HIV Gene Therapy

FDA Clearance Received for Second Phase II Trial

Published in Gene Therapy Weekly, May 20th, 1996

Cell Genesys, Inc., Foster City, California, announced that it received clearance from the U.S. Food and Drug Administration (FDA) to open for enrollment a second Phase II clinical trial for the company's AIDS gene therapy based on an Investigational New Drug application (IND) filed in March 1996.

The trial tests the company's commercial approach to this therapy, in which a patient's own T cells are collected, genetically modified to recognize and destroy HIV infected cells and returned to that same patient as AIDS gene therapy.

Drs. Steven Deeks and Paul Volberding, clinical investigators at the University of California, San Francisco and San...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1996-05-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry